PMID- 10391094
OWN - NLM
STAT- MEDLINE
DCOM- 19990719
LR  - 20190513
IS  - 0910-5050 (Print)
IS  - 1876-4673 (Electronic)
IS  - 0910-5050 (Linking)
VI  - 90
IP  - 5
DP  - 1999 May
TI  - Reduction of end-stage malignant glioma by injection with autologous cytotoxic T 
      lymphocytes.
PG  - 536-45
AB  - Autologous cytotoxic T lymphocytes (CTL) against primary-cultured malignant 
      gliomas were generated from peripheral blood mononuclear cells in vitro in 4 
      patients. Activities of the CTL were highly specific to the corresponding 
      autologous glioma and were inhibited, in one patient, with antibodies against 
      CD3, CD8 and MHC-class I molecules. When the CTL were injected 3 times into the 
      primary-tumor-resected cavity via an Ommaya tube, reduction of the recurrent 
      tumors with magnetic resonance imaging (MRI)-measured volumes exceeding 45 cm3 
      was observed in 3 patients. In a patient with glioblastoma multiforme (GBM), the 
      tumor volume (estimated, 130 cm3) was rapidly reduced to 1/3, although 
      re-recurrence of the tumor followed 40 days later. A slight but distinct rapid 
      reduction of the tumor volume was observed in another GBM patient and in an 
      anaplastic astrocytoma patient; essentially no change was observed in a further 
      GBM patient. These results suggest that adoptive immunotherapy with autologous 
      CTL will be clinically effective against end-stage malignant gliomas.
FAU - Tsurushima, H
AU  - Tsurushima H
AD  - Department of Neurosurgery, Institute of Clinical Medicine, University of 
      Tsukuba, Tsukuba Science City, Ibaraki.
FAU - Liu, S Q
AU  - Liu SQ
FAU - Tuboi, K
AU  - Tuboi K
FAU - Matsumura, A
AU  - Matsumura A
FAU - Yoshii, Y
AU  - Yoshii Y
FAU - Nose, T
AU  - Nose T
FAU - Saijo, K
AU  - Saijo K
FAU - Ohno, T
AU  - Ohno T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Cancer Res
JT  - Japanese journal of cancer research : Gann
JID - 8509412
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Surface)
SB  - IM
MH  - Adult
MH  - Antigens, CD/blood
MH  - Antigens, Surface/blood
MH  - Disease Progression
MH  - Female
MH  - Glioblastoma/pathology/*therapy
MH  - Humans
MH  - Immunophenotyping
MH  - *Immunotherapy, Adoptive
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/*transplantation
MH  - Transplantation, Autologous
PMC - PMC5926095
EDAT- 1999/07/03 00:00
MHDA- 1999/07/03 00:01
PMCR- 1999/05/01
CRDT- 1999/07/03 00:00
PHST- 1999/07/03 00:00 [pubmed]
PHST- 1999/07/03 00:01 [medline]
PHST- 1999/07/03 00:00 [entrez]
PHST- 1999/05/01 00:00 [pmc-release]
AID - S091050509980115X [pii]
AID - CAE536 [pii]
AID - 10.1111/j.1349-7006.1999.tb00781.x [doi]
PST - ppublish
SO  - Jpn J Cancer Res. 1999 May;90(5):536-45. doi: 10.1111/j.1349-7006.1999.tb00781.x.